Garadacimab - Latest Advances

ANDEMBRY (garadacimab-gxii).

Journal: Clinical therapeutics

Published: July 23, 2025

Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema.

Journal: Journal of comparative effectiveness research

Published: July 10, 2025

Pharmacological characteristics and clinical trial results of garadacimab (anti-activated factor XII monoclonal antibody) for long-term prophylaxis of hereditary angioedema

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Published: July 09, 2025

Comment on: "A national survey of four decades of hereditary angioedema prophylaxis" - The emerging role of Garadacimab.

Journal: Clinical immunology (Orlando, Fla.)

Published: June 19, 2025

The potential of factor XII inhibitors in preventing hereditary angioedema attacks.

Journal: Expert opinion on biological therapy

Published: May 24, 2025

Garadacimab improves long-term health-related quality of life in patients with hereditary angioedema.

Journal: Allergy and asthma proceedings

Published: May 17, 2025

Becoming attack-free further improves health-related quality of life in patients with hereditary angioedema receiving garadacimab.

Journal: Allergy and asthma proceedings

Published: May 17, 2025

Network Meta-Analysis of Pharmacological Therapies for Long-Term Prophylactic Treatment of Patients with Hereditary Angioedema.

Journal: Drugs in R&D

Published: May 06, 2025

Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations.

Journal: The Journal of allergy and clinical immunology

Published: April 08, 2025

Garadacimab: First Approval.

Journal: Drugs

Published: March 25, 2025

Effect of heparins, DOACs, and FXII/FXI inhibitors on catheter-initiated thrombin generation in PRP: an in vitro study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: March 14, 2025

Effect of heparins, direct oral anticoagulants, and factor XII/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: March 14, 2025

Filters

ANDEMBRY (garadacimab-gxii).

ANDEMBRY (garadacimab-gxii).

Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema.

Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema.

Pharmacological characteristics and clinical trial results of garadacimab (anti-activated factor XII monoclonal antibody) for long-term prophylaxis of hereditary angioedema

Pharmacological characteristics and clinical trial results of garadacimab (anti-activated factor XII monoclonal antibody) for long-term prophylaxis of hereditary angioedema

Comment on: "A national survey of four decades of hereditary angioedema prophylaxis" - The emerging role of Garadacimab.

Comment on: "A national survey of four decades of hereditary angioedema prophylaxis" - The emerging role of Garadacimab.

The potential of factor XII inhibitors in preventing hereditary angioedema attacks.

The potential of factor XII inhibitors in preventing hereditary angioedema attacks.

Garadacimab improves long-term health-related quality of life in patients with hereditary angioedema.

Garadacimab improves long-term health-related quality of life in patients with hereditary angioedema.

Becoming attack-free further improves health-related quality of life in patients with hereditary angioedema receiving garadacimab.

Becoming attack-free further improves health-related quality of life in patients with hereditary angioedema receiving garadacimab.

Network Meta-Analysis of Pharmacological Therapies for Long-Term Prophylactic Treatment of Patients with Hereditary Angioedema.

Network Meta-Analysis of Pharmacological Therapies for Long-Term Prophylactic Treatment of Patients with Hereditary Angioedema.

Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations.

Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations.

Garadacimab: First Approval.

Garadacimab: First Approval.

Effect of heparins, DOACs, and FXII/FXI inhibitors on catheter-initiated thrombin generation in PRP: an in vitro study.

Effect of heparins, DOACs, and FXII/FXI inhibitors on catheter-initiated thrombin generation in PRP: an in vitro study.

Effect of heparins, direct oral anticoagulants, and factor XII/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study.

Effect of heparins, direct oral anticoagulants, and factor XII/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study.